For Immediate Release
Chicago, IL – October 8, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Hewlett-Packard Company (HPQ), IBM Corp (IBM), Lexmark (LXK), Canon (CAJ) and Sigma-Aldrich Corporation (SIAL).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst Blog:
HP Projects Dull 2013
Computer maker Hewlett-Packard Company’s (HPQ) CEO Meg Whitman rang an alarm for investors as she announced that fiscal 2013 earnings may be expected to plunge over 10%.
The discouraging outlook also included possibilities of declining revenues in every business division, apart from software. The announcement battered the company’s shares, which slumped 13.0% to close at $14.91 on Wednesday, the lowest level since November 2002.
The company expects non-GAAP profit in the range of $3.40 to $3.60 per share for fiscal 2013. Moreover, in GAAP terms, HP is expecting $2.10 to $2.30 a share after charges of $1.30 per share.
Whitman said that investors should not expect a recovery until fiscal 2014, when current investments would generate returns. She also said that high executive turnover in recent years have dampened HP’s business.
HP is particularly bearish on the enterprise business. The company projects enterprise services revenue to decline 11.0% to 13.0% during fiscal 2013. Operating margins are estimated to range from break even to 3.0%.
Some industry experts commented that the competitive PC market has pulled down its margins significantly and reduction in IT spending is another headwind. Also, a declining personal computer business has largely affected HP’s business activity.
HP’s outlook looks particularly bleak when compared with that, IBM Corp (IBM), which raised its full-year 2013 earnings outlook.
Hewlett-Packard’s third quarter 2012 earnings per share exceeded the Zacks Consensus Estimate, but revenues declined compared with the year-ago period. Results were negatively impacted by macroeconomic factors, lower order renewal, a massive write-down charge and low bookings. However, we believe that the restructuring initiatives taken up by the company is encouraging and should improve margins going forward.
During the quarter the company took some major steps to focus on strategic priorities. It is also taking innovative steps to manage costs, drive growth and improve the health of its balance sheet.
On the other hand, the printer business looks challenging, with competitors such as Lexmark (LXK) and Canon (CAJ) regularly coming up with new products. In addition, the increasing availability of low-cost refilling options for toners and cartridges poses a threat for HP. Also, margins in the services business are likely to remain weak this year and the macroeconomic trends continue to work against it.
Currently, HP has a Zacks #3 Rank, implying a short-term Hold rating.
Sigma Intros Stem Cell Medium
Sigma Life Science, the innovative biological products and services research wing of Sigma-Aldrich Corporation (SIAL), has announced the launch of Stemline pluripotent culture medium, a human pluripotent stem cell culture medium which provides a suitable environment for the long-term maintenance and growth of healthy pluripotent stem cells.
Sigma-Aldrich stated that the Stemline pluripotent stem cell culture medium is serum-free, consists of fully-defined components and has 80% less basic fibroblast growth factor compared to the leading pluripotent stem cell culture medium. This provides a favorable environment for long-term maintenance of optimal growth rates, viability and pluripotency.
The stem cell research community usually complains of the high costs of media for pluripotent stem cells. However, Sigma-Aldrich’s Stemline pluripotent culture medium performs as good as the leading medium for maintaining pluripotency and optimal growth rates and is available at comparatively lower costs than the conventional media.
It is also found that cultured pluripotent stem cells show all the established pluripotency markers and maintain proper karyotype and the ability to distinguish into each of the three germ layers. The novel Stemline media strengthens Sigma-Aldrich's position as one of the largest global providers of cell culture media.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com